Holen Sie sich die Stockscreener-App
100.64
1.59%
-1.63
Handel nachbörslich:
100.77
0.13
+0.13%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt KMB?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$102.27
Offen:
$102.175
24-Stunden-Volumen:
15.95M
Relative Volume:
5.08
Marktkapitalisierung:
$33.39B
Einnahmen:
$18.08B
Nettoeinkommen (Verlust:
$1.81B
KGV:
17.05
EPS:
5.904
Netto-Cashflow:
$2.10B
1W Leistung:
-16.59%
1M Leistung:
-17.90%
6M Leistung:
-22.79%
1J Leistung:
-24.75%
1-Tages-Spanne:
$99.60
$102.75
1-Wochen-Bereich:
$99.60
$123.09
52-Wochen-Spanne:
$99.60
$150.45
Kimberly Clark Corp Stock (KMB) Company Profile
Firmenname
Kimberly Clark Corp
Sektor
Telefon
(972) 281-1200
Adresse
351 PHELPS DRIVE, IRVING, TX
Vergleichen Sie KMB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KMB
Kimberly Clark Corp
|
100.64 | 33.94B | 18.08B | 1.81B | 2.10B | 5.904 |
|
PG
Procter Gamble Co
|
147.17 | 345.88B | 84.93B | 16.86B | 14.94B | 6.8506 |
|
UL
Unilever Plc Adr
|
60.81 | 148.76B | 64.99B | 6.71B | 6.53B | 2.4355 |
|
CL
Colgate Palmolive Co
|
76.55 | 60.44B | 20.10B | 3.04B | 3.37B | 3.569 |
|
KVUE
Kenvue Inc
|
15.97 | 30.92B | 15.14B | 1.42B | 1.63B | 0.7361 |
Kimberly Clark Corp Stock (KMB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-18 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-08 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-23 | Eingeleitet | TD Cowen | Buy |
| 2024-06-24 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2024-06-13 | Hochstufung | BofA Securities | Underperform → Buy |
| 2024-06-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-03-01 | Fortgesetzt | Goldman | Buy |
| 2023-12-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-11-17 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-12 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-22 | Eingeleitet | HSBC Securities | Hold |
| 2023-03-20 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2023-02-17 | Eingeleitet | Citigroup | Sell |
| 2023-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-06 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2022-10-18 | Eingeleitet | Evercore ISI | In-line |
| 2022-10-12 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2022-09-14 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Herabstufung | Bernstein | Mkt Perform → Underperform |
| 2022-01-27 | Bestätigt | Citigroup | Sell |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2022-01-27 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-11 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2021-10-26 | Herabstufung | Berenberg | Buy → Hold |
| 2021-09-09 | Eingeleitet | HSBC Securities | Hold |
| 2021-06-24 | Eingeleitet | UBS | Neutral |
| 2021-05-14 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-26 | Herabstufung | Argus | Buy → Hold |
| 2021-01-20 | Eingeleitet | Bernstein | Mkt Perform |
| 2020-12-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-10-16 | Eingeleitet | Berenberg | Buy |
| 2020-10-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-30 | Hochstufung | Jefferies | Hold → Buy |
| 2019-10-23 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2019-09-27 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-09-23 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-07-24 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2019-06-19 | Bestätigt | BofA/Merrill | Neutral |
| 2019-04-23 | Hochstufung | Argus | Hold → Buy |
| 2019-04-23 | Hochstufung | Macquarie | Neutral → Outperform |
| 2019-02-11 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-01-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2018-09-20 | Eingeleitet | Atlantic Equities | Underweight |
| 2018-08-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-08-15 | Herabstufung | Societe Generale | Buy → Hold |
| 2018-06-21 | Eingeleitet | Morgan Stanley | Underweight |
| 2017-12-14 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Kimberly Clark Corp Aktie (KMB) Neueste Nachrichten
Kimberly-Clark deal a vote of confidence in Trump’s economy - Washington Times
Kimberly-Clark/Kenvue Deal: What Could Stop It - Barron's
Kleenex Wipes Away Kenvue’s Tears: North Texas’ Kimberly-Clark To Buy Embattled Tylenol Maker - Dallas Express
Kimberly-Clark to buy Tylenol maker Kenvue in $48.7-B deal - MSN
Kimberly-Clark to acquire Tylenol maker Kenvue in $48.7 billion deal - 95.3 X95
Kimberly-Clark, Kenvue’s $48.7B deal among recent multibillion-dollar M&A - Manufacturing Dive
Kimberly-Clark transformation adds complexity and uncertainty, says Evercore - Investing.com
The Gamble Behind a Big Takeover of Tylenol’s Maker - The New York Times
Kimberly-Clark: Can The Kenvue Acquisition Erase The Decade Of Disappointment? (KMB) - Seeking Alpha
Kimberly-Clark acquires Kenvue for USD 48.7 billion to strengthen its leadership in personal care and health - Tissue Online North America
Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn - Yahoo Finance
Kenvue Stock Rose 12% On Possible $48.7 Billion Acquisition by Kimberly-Clark - TIKR.com
This Kimberly-Clark Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Kimberly-Clark Takeover Offers $48 Billion of Pain Relief to Tylenol-Maker Kenvue - The Daily Upside
Kenvue (KVUE) Soars 12% on $48.7-Billion Kimberly-Clark Merger - Insider Monkey
Kimberly-Clark To Acquire Kenvue In $48.7 Billion Mega Deal - Yahoo Finance
Kimberly-Clark (NASDAQ:KMB) Sets New 52-Week LowTime to Sell? - MarketBeat
Kimberly-Clark to acquire Band-Aid, Neutrogena owner Kenvue for $48.7 billion - Storyboard18
Kimberly-Clark (KMB): Assessing Value After Recent 17% Share Price Slide - Yahoo Finance
iA Global Asset Management Inc. Sells 18,949 Shares of Kimberly-Clark Corporation $KMB - MarketBeat
Kimberly-Clark Stock Drops Premarket Even As Analysts, Retail Investors Turn Positive On $49B Kenvue Deal - Stocktwits
Kimberly-Clark to acquire Tylenol's parent company in nearly $49B deal - NPR
Kimberly-Clark Bets $48.7B on Health Giant Kenvue - Value The Markets
Kimberly-Clark Corporation $KMB Shares Bought by Atria Investments Inc - MarketBeat
Kimberly-Clark to buy Kenvue - The Arkansas Democrat-Gazette
These 2 Dividend Kings Are Combining in a $48.7 Billion Megadeal. Is It A Win-Win for Dividend Investors? - The Motley Fool
Can machine learning forecast Kimberly Clark Corporation recoveryEarnings Summary Report & High Accuracy Trade Signal Alerts - newser.com
Kimberly-Clark to acquire Kenvue, creating a $32 billion leader - PULPAPERnews.com
Is Kimberly Clark Corporation stock a buy in volatile marketsJuly 2025 Levels & Technical Entry and Exit Tips - newser.com
Kimberly-Clark buying Kenvue in $48.7 billion consumer brands deal - TelegraphHerald.com
Kimberly-Clark is taking Tylenol in $49 billion deal - Morning Brew
Kenvue’s Tylenol Litigation Overhang Doesn’t Dim ‘Generational Opportunity’ For Kimberly-Clark - Citeline News & Insights
Kenvue Shares Soar 16% After Inking $48.7B Deal With Kimberly-Clark - Stocktwits
Will Kimberly Clark Corporation stock outperform Dow Jones index2025 Short Interest & Fast Gaining Stock Reports - newser.com
Latham Advises on Financing for Kimberly-Clark’s Acquisition of Kenvue to Create a US$32 Billion Global Health and Wellness Leader - Legal Desire Media and Insights
The CEO Behind Kimberly-Clark’s $40 Billion Gamble on Tylenol MakerWSJ - The Wall Street Journal
Palantir, Kimberly-Clark, Hims & Hers, Navitas And Cipher Mining: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Kimberly-Clark to buy Kenvue in US$48.7 billion deal - Marketing-Interactive
Kimberly-Clark, Eaton Put Dealmakers on Cusp of $4 Trillion - Bloomberg
Kimberly-Clark Bets $50 Billion On Health And Beauty With Kenvue Deal - Finimize
Kimberly-Clark buys Kenvue; combined company expected to generate $32-billion a year - Yahoo News Canada
Kimberly-Clark to Acquire Kenvue - WWD
North Texas’ Kimberly-Clark To Acquire Tylenol Maker in $40B Deal - Dallas Innovates
Kimberly-Clark to Acquire Kenvue in $48.7 Billion Deal - BeautyMatter
Kimberly-Clark "considered all risks" before Tylenol deal - Axios
Kenvue’s legal risks loom over planned acquisition by Kimberly-Clark - Reuters
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm - The New York Times
Kimberly-Clark acquires Neutrogena-owner Kenvue - FashionNetwork USA
Kimberly-Clark Strikes $40 Billion Deal for Tylenol Maker Kenvue - The Wall Street Journal
Kimberly-Clark: Kenvue Deal Comes With Considerable Risks, but Shares Look Cheap - Morningstar
Kimberly-Clark’s $50 billion leap into health and beauty tests investor faith - Reuters
Finanzdaten der Kimberly Clark Corp-Aktie (KMB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):